Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Jazz Pharmaceuticals (NASDAQ: JAZZ ) soared 10% today after the specialty biopharmaceutical company agreed to acquire Italy-based rare disease drug developer Gentium for $1 billion.
So what: The all-cash deal values Gentium at $57 per share, representing a premium of just 2% to its closing price on Thursday. Jazz is making the move to gain access to Gentium's rare-disease portfolio -- particularly lead drug Defitelio which received European approval in October -- and judging by today's big jump, Mr. Market is thrilled with the price that management is paying to do it.
Now what: Jazz expects the transaction to be immediately accretive to its adjusted earnings per share. "Incorporating Gentium into Jazz Pharmaceuticals is a strong strategic fit as Defitelio would diversify our development and commercial portfolio and complement our clinical experience in hematology/oncology and our expertise in reaching targeted physicians who treat serious medical conditions," said Jazz Chairman and CEO Bruce Cozadd. "Because Defitelio is already approved in the EU, the acquisition would add a new orphan product that has potential for short- and long-term revenue generation, high growth and expansion of our multi-national commercial platform." So while Gentium is likely all popped out at this point, biotech savvy Fools might want to look into Jazz's newly bolstered portfolio.
More reliable ways to wealth
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.